Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Fate Therapeutics Inc’s stock clocked out at $1.30, down -5.11% from its previous closing price of $1.37. In other words, the price has decreased by -$5.11 from its previous closing price. On the day, 1.34 million shares were traded. FATE stock price reached its highest trading level at $1.4 during the session, while it also had its lowest trading level at $1.28.
Ratios:
To gain a deeper understanding of FATE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.29 and its Current Ratio is at 8.29. In the meantime, Its Debt-to-Equity ratio is 0.27 whereas as Long-Term Debt/Eq ratio is at 0.25.
On June 17, 2024, Piper Sandler Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $4 to $6.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jan 10 ’25 when Bressi Jerome Charles sold 5,980 shares for $1.55 per share. The transaction valued at 9,269 led to the insider holds 270,203 shares of the business.
TAHL CINDY sold 5,654 shares of FATE for $8,764 on Jan 10 ’25. The insider now owns 336,707 shares after completing the transaction at $1.55 per share. On Jan 10 ’25, another insider, Valamehr Bahram, who serves as the President and CEO of the company, sold 8,705 shares for $1.54 each. As a result, the insider received 13,406 and left with 349,364 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FATE now has a Market Capitalization of 148062192 and an Enterprise Value of -49879368. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.01 while its Price-to-Book (P/B) ratio in mrq is 0.41. Its current Enterprise Value per Revenue stands at -3.709 whereas that against EBITDA is 0.303.
Stock Price History:
The Beta on a monthly basis for FATE is 2.02, which has changed by -0.7955975 over the last 52 weeks, in comparison to a change of 0.22208416 over the same period for the S&P500. Over the past 52 weeks, FATE has reached a high of $8.83, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -30.87%, while the 200-Day Moving Average is calculated to be -59.56%.
Shares Statistics:
It appears that FATE traded 3.24M shares on average per day over the past three months and 1330800 shares per day over the past ten days. A total of 113.88M shares are outstanding, with a floating share count of 97.84M. Insiders hold about 14.09% of the company’s shares, while institutions hold 87.50% stake in the company. Shares short for FATE as of 1736899200 were 12698496 with a Short Ratio of 3.92, compared to 1734048000 on 12186948. Therefore, it implies a Short% of Shares Outstanding of 12698496 and a Short% of Float of 12.790000000000001.
